Jabil Healthcare Signs Strategic Collaboration Agreement with E3D, Expanding Pharmaceutical Market Offering
Jabil Healthcare has announced a strategic collaboration with E3D, gaining exclusive rights to develop a reusable auto-injector and connected variants. This partnership aims to enhance the development of connected drug delivery devices, offering patient-centric benefits and a range of dosing volumes. Jabil's expertise in manufacturing will support the commercialization of these innovative solutions. The agreement positions Jabil to expand its market offering and strengthen its capabilities in digital health technologies, benefiting both the company and its healthcare clients.
- Jabil Healthcare secures exclusive rights to develop a reusable auto-injector, enhancing its product offerings.
- Partnership with E3D enables Jabil to innovate in digital health technologies, improving patient-centric solutions.
- Jabil's existing relationships with leading healthcare brands bolster its capabilities in large New Product Introductions.
- None.
Jabil Healthcare, a division of Jabil Inc. (NYSE: JBL), today announced it has entered a strategic collaboration agreement with global drug delivery device company E3D, a member of the Elcam Medical Group, which gives Jabil access to E3D’s reusable mechanical auto-injector. Under the terms of this deal, Jabil has secured exclusive rights to develop a high-volume reusable auto-injector and connected variants.
The agreement enables Jabil Healthcare to further develop connected auto-injectors for a range of dosing volumes and patient-centric benefits, ultimately creating a platform of devices. Jabil Healthcare applies its expertise to help customers through the design, development and manufacture of some of the most complex and innovative drug delivery devices in the market.
“Our collaboration with E3D enhances Jabil’s development of pharmaceutical solutions that move us into the future of connected, digital devices that are more intuitive, economical and sustainable,” said James O’Gorman, vice president, Pharmaceutical Delivery Systems (PDS), Jabil Healthcare. “This is an exciting expansion of our relationship with E3D that will benefit our market offering and healthcare customers alike.”
“As a leader in the healthcare arena, Jabil Healthcare is the perfect partner for us and for a drug delivery market that requires the highest levels of competence, experience and scale in manufacturing,” said Tsachi Shaked, general manager of E3D. “Our complementary expertise in electronics, manufacturing and data analysis is the type of collaboration that should help speed advances and adoption of digital health technologies.”
Jabil Healthcare’s Pharmaceutical Delivery Systems business is relied on by many of the world’s leading healthcare brands to execute large New Product Introductions (NPI) and ramp into commercial production, applying proven manufacturing processes to reduce risk and overall cost. Together, Jabil Healthcare and E3D form a comprehensive offering of pre-launch support, including full global commercial supply, lifecycle management, final product assembly, labeling and legal manufacturing services.
About Jabil
Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit www.jabil.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005104/en/
FAQ
What is Jabil's recent collaboration with E3D about?
How does the Jabil and E3D partnership impact drug delivery devices?
What are the benefits of Jabil's collaboration with E3D?
What type of expertise does Jabil bring to the partnership with E3D?
